Vanda Pharmaceuticals | VNDA - Ebitda


Vanda Pharmaceuticals reported $-8.31M in EBITDA for its fiscal quarter ending in December of 2024.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Moderna USD -790M 582M Dec/2025
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Takeda JPY 150.25B 297.88B Mar/2026
Teva Pharmaceutical Industries USD 1.06B 582M Mar/2026
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Veracyte USD 42.8M 488K Mar/2026